[HTML][HTML] The cardiac lymphatic system stimulates resolution of inflammation following myocardial infarction

JM Vieira, S Norman, CV Del Campo… - The Journal of …, 2018 - Am Soc Clin Investig
JM Vieira, S Norman, CV Del Campo, TJ Cahill, DN Barnette, M Gunadasa-Rohling…
The Journal of clinical investigation, 2018Am Soc Clin Investig
Myocardial infarction (MI) arising from obstruction of the coronary circulation engenders
massive cardiomyocyte loss and replacement by non-contractile scar tissue, leading to
pathological remodeling, dysfunction, and ultimately heart failure. This is presently a global
health problem for which there is no effective cure. Following MI, the innate immune system
directs the phagocytosis of dead cell debris in an effort to stimulate cell repopulation and
tissue renewal. In the mammalian adult heart, however, the persistent influx of immune cells …
Myocardial infarction (MI) arising from obstruction of the coronary circulation engenders massive cardiomyocyte loss and replacement by non-contractile scar tissue, leading to pathological remodeling, dysfunction, and ultimately heart failure. This is presently a global health problem for which there is no effective cure. Following MI, the innate immune system directs the phagocytosis of dead cell debris in an effort to stimulate cell repopulation and tissue renewal. In the mammalian adult heart, however, the persistent influx of immune cells, coupled with the lack of an inherent regenerative capacity, results in cardiac fibrosis. Here, we reveal that stimulation of cardiac lymphangiogenesis with VEGF-C improves clearance of the acute inflammatory response after MI by trafficking immune cells to draining mediastinal lymph nodes (MLNs) in a process dependent on lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1). Deletion of Lyve1 in mice, preventing docking and transit of leukocytes through the lymphatic endothelium, results in exacerbation of chronic inflammation and long-term deterioration of cardiac function. Our findings support targeting of the lymphatic/immune cell axis as a therapeutic paradigm to promote immune modulation and heart repair.
The Journal of Clinical Investigation